Plain-English translation of NCT03109288 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is a research study testing a new approach to treating multiple sclerosis in people whose disease continues to worsen or who have lasting disability despite current treatments. Instead of giving everyone the same medication, doctors will analyze markers in your spinal fluid to understand which biological processes are driving your individual disease, then prescribe personalized combinations of medications designed to target those specific processes.
Current multiple sclerosis medications work well for many patients early on, but their effectiveness declines significantly with age and don't address all the different ways the disease progresses in different people. Researchers believe that combining medications tailored to each patient's unique disease mechanisms — similar to how heart disease is treated — could be more effective than any single drug.
You likely qualify if…
You likely don't qualify if…
You will start by having your spinal fluid analyzed to identify which disease processes are active in your particular case. Based on those results, you will then take either one or two study medications (or continue your current disease-modifying therapy alongside study drugs) for a period of time while researchers monitor how you respond. You'll have regular clinical visits and periodic spinal fluid tests to measure whether your disease progression changes and how your biomarkers respond to the treatment.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States